Nyrada logo

Nyrada(ASX) NYR

Market CapA$121.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)+109%
5 Year+104%
1 Year+60%
1 Month-30%
A$0.48
-2.04%
-0.01Today
Nyrada last closing stock price
MetricPriceDate
Last closeAUD 0.482026-10-09
Nyrada stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-7.69%AUD 0.522026-10-02
1 month-29.93%AUD 0.692026-09-09
3 month+11.63%AUD 0.432026-07-10
Year to date-57.14%AUD 1.122025-12-31
1 year+60%AUD 0.302025-10-09
3 year+2,300%AUD 0.022023-10-10
5 year+104.26%AUD 0.242021-10-08
Since inception+108.51%AUD 0.242020-01-16

Nyrada Financials at a Glance

Market Cap

A$121.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$2.40M

Net Income (TTM)

-A$11.39M

EPS (TTM)

-A$0.03

P/E Ratio

-17.88

Dividend

A$0.00

Beta (Volatility)

-0.18 (Low)

Price

A$0.48

Volume

287,874

Open

A$0.50

Previous Close

A$0.48

Daily Range

A$0.48 - A$0.51

52-Week Range

A$0.31 - A$1.44

Estimated Earnings Date

Feb 16, 2026

NYR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Nyrada

Nyrada Inc. is a pre-clinical stage drug development company focused on creating small molecule drugs for cardiovascular and neurological diseases. The company is based in Sydney, Australia, and is advancing its lead candidate, Xolatryp, which has completed phase 1 clinical trials for neuroprotection and cardioprotection.

Products and Services
  • Xolatryp: A small molecule drug targeting neuroprotection and cardioprotection
  • Research and development of innovative therapies for cardiovascular diseases
  • Focus on neurological disease treatments, including traumatic brain injury
Growth Outlook
  • Strong pipeline with potential for significant market impact in healthcare
  • Recent clinical trials demonstrate promising results for lead candidate
  • Increasing demand for innovative treatments in cardiovascular and neurological sectors
Financial Highlights
  • Recent quarterly revenue of AUD 0, reflecting ongoing development phase
  • Cash and cash equivalents of AUD 8.38 million as of June 2026
  • Current ratio of 11.94 indicates strong liquidity position
Nyrada Inc. is positioned in the biotechnology sector, focusing on critical health issues that affect millions globally. The company’s lead candidate, Xolatryp, has shown potential in early clinical trials, which may pave the way for future advancements in treatment options. With a robust cash position, Nyrada is well-equipped to continue its research and development efforts. The increasing demand for innovative therapies in the healthcare sector further supports the company's growth potential. Investors may find Nyrada Inc. an intriguing opportunity within the biotechnology landscape.
AI Generated • Oct 8, 2026

Industry

Pharmaceuticals

CEO

James Bonnar

Headquarters

Sydney, NSW 2000, AU

NYR Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-67.47%

Return on Capital

-89.83%

Return on Assets

-62.76%

Earnings Yield

-5.59%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$121.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

247.09M

Volume

287.87K

Avg. Volume

337.09K

Financials (TTM)

Gross Profit

-A$1.98M

Operating Income

-A$17.79M

EBITDA

-A$13.59M

Operating Cash Flow

-A$9.55M

Capital Expenditure

-A$9.82K

Free Cash Flow

-A$9.56M

Cash & ST Invst.

A$8.38M

Total Debt

A$0.00

Nyrada Performance Analysis

Nyrada annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 0N/A
20262026-06-30AUD 0N/A
Nyrada sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-6.2%
Q42025-06-30100.3%
Q22025-12-31-100.0%
Q42026-06-30N/A
Nyrada annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.0596.5%
20242024-06-30AUD -0.01-83.0%
20252025-06-30AUD -0.02185.9%
20262026-06-30AUD -0.0312.3%
Nyrada sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31-37.2%
Q42025-06-3011.6%
Q22025-12-31-19.3%
Q42026-06-30-1.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$0.00

-100.0%

Gross Profit

-A$1.74K

+24.9%

Gross Margin

0.00%

N/A

Market Cap

A$121.08MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$30.27K

N/A

Employees

4,000

N/A

Net Income

-A$3.36M

-119.8%

EBITDA

-A$4.57M

-93.5%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$8.38M

+75.8%

Total Debt

A$0.00

N/A

Accounts Receivable

A$1.80M

+76.0%

Inventory

A$0.00

N/A

Long Term Debt

A$0.00

N/A

Short Term Debt

A$0.00

N/A

Return on Assets

-62.76%

N/A

Return on Invested Capital

-89.92%

N/A

Free Cash Flow

-A$45.56K

+97.3%

Operating Cash Flow

-A$37.97K

+97.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ATH.AXAlterity Therapeutics Limited
A$0.36-2.74%
NUZ.AXNeurizon Therapeutics Limited
A$0.09+1.66%
ALA.AXArovella Therapeutics Limited
A$0.05+8.33%
ACW.AXActinogen Medical Limited
A$0.06+3.77%

Trending Stocks

Symbol / CompanyPricePrice Chg
VEEAVeea
$5.99+54.79%
TAT&T
$22.72-7.63%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$33.12-1.98%
SPCXSpace Exploration Technologies
$164.43+2.40%

Questions About NYR

What is the current price of Nyrada?

Nyrada is trading at A$0.48 per share.

What is the 52-week range for Nyrada?

Over the past 52 weeks, Nyrada has traded between A$0.31 and A$1.44.

How much debt does Nyrada have?

As of the most recent reporting period, Nyrada reported total debt of A$0.00.

How much cash does Nyrada have on hand?

Nyrada reported A$8.38M in cash and cash equivalents in its most recent financial results.

What is Nyrada’s dividend yield?

Nyrada does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.